In recent years, new treatment options for type 2 diabetes have resulted in a paradigm shift in how blood sugar levels are managed. Commercial payers have witnessed a surge in the overall costs of their prescription drug benefits, driven largely by spending on antidiabetic medications, including glucagon-like peptide-1 agonists (GLP-1) and sodium-glucose cotransporter-2 SGLT-2 medications. To help plan sponsors better understand the cost drivers for these drugs, this white paper provides historical trends for antidiabetic medications from 2016 through 2023, with projected trends for 2024. It discusses:

• A brief history of antidiabetic drug classes
• Data sources
• Unit cost
• Other considerations
• Prevalence of type 2 diabetes

This report was commissioned by Virta Health Corporation.